A watershed moment came in March when the U.S. Food and Drug Administration (FDA) approved Spravato, or esketamine, a ketamine nasal spray for adults with treatment-resistant major depression.

But before that she takes a ketamine nasal spray — a drug she says helps manage her treatment-resistant depression. "You feel quite funny, sort of out of your body for a little while," Ms Neale ...

The FDA updated a warning on the label of esketamine nasal spray (Spravato) about the long-term cognitive and memory ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato ... The drug is the first ketamine-based medicine approved to treat depression. Ketamine has long been seen as a potential ...

Ketamine has a reputation as a party drug but is licensed as an anaesthetic. The study found use of the drug via a nasal spray led to "significant" improvements in depressive symptoms in the first ...

Researchers have developed a promising nasal spray therapy targeting neuroinflammation in Alzheimer’s disease, potentially ...

Right now Ketamine is not FDA approved to treat any psychiatric disorder. But back inJuly, Johnson and Johnson did seek approval for a nasal Ketamine spray, that is currently in waiting.

A new tablet form of ketamine has shown promise in treating ... led by Weill Cornell Medicine investigators showed that a nasal spray that patients administer at home, without a physician ...

By 2010, doctors had begun prescribing the drug off-label in intravenous form, and in 2019, the FDA approved a ketamine nasal spray called Spravato. Since then, the drug has fully entered the ...